Literature DB >> 29756358

Echocardiographic parameters to identify sickle cell patients with cardio-pathology.

Simbo Chiadika1, Mary Lim-Fung1, Fiorella Llanos-Chea2, Astrid Serauto Canache2, Wei Yang2, Christina Paruthi1, Xu Zhang3, David D McPherson1, Modupe Idowu4.   

Abstract

BACKGROUND: Sickle cell disease (SCD) affects millions of people and causes chronic hemolytic anemia leading to vasculopathies such as pulmonary hypertension and abnormalities in cardiac function that increase complications and mortality. It is therefore crucial to identify cardiac abnormalities in SCD. We aimed to assess the prevalence of echocardiographic parameters in SCD to help identify cardiopulmonary risk.
METHODS: Ninety-one patients (53% male), median age of 30, body surface area (BSA) of 1.79 m2 , hemoglobin of 8.8 g/dL, and creatinine of 0.7 mg/dL identified. We retrospectively measured laboratory and echocardiographic parameters in patients with SCD : left ventricular (LV) dimensions, LV ejection fraction (LVEF), LV Myocardial Performance Index (MPI), LV Mass Index (MI), Left Atrial Volume Index (LAVI), Tricuspid Regurgitation Velocity (TRV), tricuspid annular plane systolic excursion (TAPSE), right heart dimensions.
RESULTS: Prevalence of left heart abnormalities was 32%: increased LV end-diastolic diameter (EDD), 78%: LV MPI, 21%: diastolic dysfunction, 38%: decreased LVEF, 24%: increased LVMI, and 47%: increased LAVI. Right heart abnormalities were 39%: TAPSE, 38%: increased TRV, and 59%: increased pulmonary systolic pressure (PASP). Multivariate logistic regression analysis was significant for increased LVMI and LAVI in those with hemoglobin ≤8 g/dL (odds ratio (OR) 7.4, 95% confidence interval (CI) 2.23-24.6, P = .001) and (OR 3.32, 95% CI 1.18-9.33, P = .023).
CONCLUSIONS: We confirmed increased prevalence of abnormal LVEDD, LVMI, diastolic function, LAVI, and PASP in SCD. In addition, we identified abnormal LV MPI (78%), TAPSE (29%). These parameters may be useful and readily accessible echocardiographic prognostic tools in this population.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  cardiomyopathy; diastolic function; hemoglobin; left atrial volume index; myocardial performance index; tricuspid annular plane systolic excursion

Mesh:

Year:  2018        PMID: 29756358      PMCID: PMC6136950          DOI: 10.1111/echo.14028

Source DB:  PubMed          Journal:  Echocardiography        ISSN: 0742-2822            Impact factor:   1.724


  23 in total

Review 1.  Vasculopathy and pulmonary hypertension in sickle cell disease.

Authors:  Karin P Potoka; Mark T Gladwin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-11-14       Impact factor: 5.464

Review 2.  Recommendations for chamber quantification.

Authors:  Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack Shanewise; Scott Solomon; Kirk T Spencer; Martin St John Sutton; William Stewart
Journal:  Eur J Echocardiogr       Date:  2006-02-02

Review 3.  TAPSE: An old but useful tool in different diseases.

Authors:  Elio Aloia; Matteo Cameli; Flavio D'Ascenzi; Carlotta Sciaccaluga; Sergio Mondillo
Journal:  Int J Cardiol       Date:  2016-10-05       Impact factor: 4.164

4.  Evaluation of left ventricular function in patients with sickle cell anemia.

Authors:  J L Gerry; M G Baird; N J Fortuin
Journal:  Am J Med       Date:  1976-06       Impact factor: 4.965

5.  An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.

Authors:  Elizabeth S Klings; Roberto F Machado; Robyn J Barst; Claudia R Morris; Kamal K Mubarak; Victor R Gordeuk; Gregory J Kato; Kenneth I Ataga; J Simon Gibbs; Oswaldo Castro; Erika B Rosenzweig; Namita Sood; Lewis Hsu; Kevin C Wilson; Marilyn J Telen; Laura M Decastro; Lakshmanan Krishnamurti; Martin H Steinberg; David B Badesch; Mark T Gladwin
Journal:  Am J Respir Crit Care Med       Date:  2014-03-15       Impact factor: 21.405

6.  Right ventricular systolic strain is altered in children with sickle cell disease.

Authors:  Julie Blanc; Bertrand Stos; Mariane de Montalembert; Damien Bonnet; Younes Boudjemline
Journal:  J Am Soc Echocardiogr       Date:  2012-02-16       Impact factor: 5.251

7.  Right ventricular systolic function is not the sole determinant of tricuspid annular motion.

Authors:  Angel López-Candales; Navin Rajagopalan; Neil Saxena; Beth Gulyasy; Kathy Edelman; Raveen Bazaz
Journal:  Am J Cardiol       Date:  2006-08-17       Impact factor: 2.778

Review 8.  Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis.

Authors:  Eduardo Bossone; Antonello D'Andrea; Michele D'Alto; Rodolfo Citro; Paola Argiento; Francesco Ferrara; Antonio Cittadini; Melvyn Rubenfire; Robert Naeije
Journal:  J Am Soc Echocardiogr       Date:  2012-11-08       Impact factor: 5.251

Review 9.  Cardiomyopathy With Restrictive Physiology in Sickle Cell Disease.

Authors:  Omar Niss; Charles T Quinn; Adam Lane; Joshua Daily; Philip R Khoury; Nihal Bakeer; Thomas R Kimball; Jeffrey A Towbin; Punam Malik; Michael D Taylor
Journal:  JACC Cardiovasc Imaging       Date:  2016-02-17

10.  New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function--a study in normals and dilated cardiomyopathy.

Authors:  C Tei; L H Ling; D O Hodge; K R Bailey; J K Oh; R J Rodeheffer; A J Tajik; J B Seward
Journal:  J Cardiol       Date:  1995-12       Impact factor: 3.159

View more
  2 in total

1.  Right ventricular function among South East Nigeria children with sickle cell anaemia.

Authors:  Josephat M Chinawa; Bartholomew F Chukwu; Awoere T Chinawa; Edmund N Ossai; Anthony N Ikefuna; Ann E Aronu; Egbuna O Obidike
Journal:  BMC Pediatr       Date:  2020-05-21       Impact factor: 2.125

2.  Haemoglobinopathies from the cardiac point of view.

Authors:  Minna Moreira Dias Romano
Journal:  Hematol Transfus Cell Ther       Date:  2019-07-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.